TG Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/9/2026
- Nasdaq ends sharply higher; chip surge offsets Iran worries
- Software stocks slide as Starbucks builds AI tools to replace vendor software
- Applied Materials surges as CEO signals multi-year chip boom
- Oil prices settle 2% lower as economic worries outweigh supply risks
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
- Morgan Stanley Reiterates Overweight Rating on Rocket Lab USA (RKLB), Bull Case Raised to $293
- GameStop stockholders approve share count increase to 2.5 billion
- Crude Inventory Rose 3 Million Barrels Last Week - EIA
- AI bubble fears mount as Zuckerberg admits agent delays and Burry shorts sector
- Meta falls as massive AI infrastructure spending plans overshadow chip progress
TG Therapeutics (TGTX) PT Raised to $40 at Ladenburg Thalmann
May 2, 2024 6:34 AM EDTLadenburg Thalmann analyst Matthew Kaplan raised the price target on TG Therapeutics (NASDAQ: TGTX) to $40.00 (from $39.00) while maintaining a Buy rating.
The analyst comments "Strong BRIUMVI 1Q24 revenues with >25% Q/Q growth; TGTX increased BRIUMVI 2024 revenue guidance to $270-$290 million from $220-$260 million. TG... More
